Impact of lower challenge doses of enterotoxigenic Escherichia coli on clinical outcome, intestinal colonization and immune responses in adult volunteers.
A phase II/III randomized, multicenter trial of prednisone/sirolimus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft--host disease: BMT CTN 0801.
Our site uses cookies for analytics and to improve our site and services. You can manage these cookies via your browser settings at any time. By continuing to use our site, you agree to our use of cookies. For more information, including how to change your settings, see our Cookie Policy.